Marshall Fordyce | BiotechTV

top of page

Search

Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego

Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego

Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR...

Oct 27, 2024

Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics

Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics

Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.

Feb 13, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page